Brokerages Set CureVac N.V. (NASDAQ:CVAC) PT at $6.83

CureVac N.V. (NASDAQ:CVAC) has been assigned a consensus recommendation of “Hold” from the six research firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, four have given a hold recommendation and one has given a buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $6.8333.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CureVac in a report on Tuesday, December 16th.

Institutional Investors Weigh In On CureVac

Institutional investors have recently added to or reduced their stakes in the company. Alpine Associates Management Inc. purchased a new stake in CureVac in the 2nd quarter valued at about $10,703,000. Qube Research & Technologies Ltd purchased a new stake in shares of CureVac during the second quarter valued at approximately $6,419,000. Water Island Capital LLC purchased a new stake in shares of CureVac during the second quarter valued at approximately $5,197,000. AQR Arbitrage LLC lifted its holdings in CureVac by 2,145.7% during the third quarter. AQR Arbitrage LLC now owns 991,688 shares of the company’s stock worth $5,345,000 after acquiring an additional 947,529 shares during the period. Finally, Magnetar Financial LLC purchased a new position in CureVac in the third quarter worth $3,529,000. 17.26% of the stock is owned by institutional investors.

CureVac Stock Performance

Shares of CVAC opened at $4.66 on Thursday. The firm has a market capitalization of $1.05 billion, a P/E ratio of 6.47 and a beta of 1.77. CureVac has a 52 week low of $4.00 and a 52 week high of $4.68. The stock has a 50 day moving average price of $4.68 and a two-hundred day moving average price of $5.13. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.69 and a current ratio of 3.70.

CureVac (NASDAQ:CVAC) last announced its earnings results on Monday, November 24th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.07. CureVac had a negative return on equity of 23.03% and a net margin of 199.92%.The company had revenue of $63.53 million for the quarter, compared to analysts’ expectations of $21.40 million. Equities analysts forecast that CureVac will post 0.72 earnings per share for the current fiscal year.

CureVac Company Profile

CureVac N.V. is a clinical-stage biopharmaceutical company that specializes in the research, development and commercialization of messenger RNA (mRNA)-based medicines and vaccines. Leveraging its proprietary mRNA platform, the company seeks to harness the body’s natural protein production processes to address a range of diseases, with particular emphasis on prophylactic vaccines for infectious diseases as well as therapeutic candidates in oncology. CureVac’s technology is designed to deliver optimized mRNA sequences for in vivo expression, aiming to improve stability, translational efficiency and immunogenicity compared with conventional approaches.

Founded in 2000 and headquartered in Tübingen, Germany, CureVac has built a pipeline spanning early- to late-stage clinical programs.